[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wang Jianliu\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100649230","phase-2-sintilimab-monotherapy-in-patients-with-stage-i-ii-msi-hdmmr-endometrial-cancer-100649230",false,"NCT07731607","Sintilimab Monotherapy in Patients With Stage I-II MSI-H\u002FdMMR Endometrial Cancer","Inclusion Criteria:\n\n1. Aged 18-75 years.\n2. Histopathologically confirmed endometrial cancer, with pathological types including endometrioid, serous, clear cell, undifferentiated, dedifferentiated, or carcinosarcoma.\n3. Laboratory-confirmed dMMR (mismatch repair deficient) endometrial cancer (loss of MLH1\u002FPMS2\u002FMSH2\u002FMSH6 protein expression by immunohistochemistry) or MSI-H (microsatellite instability-high by PCR or NGS).\n4. Stage I-II according to the FIGO 2023 staging system.\n5. At least one measurable lesion (RECIST 1.1 criteria).\n6. ECOG performance status 0-1, with a life expectancy of ≥12 months.\n7. Strong desire for uterine preservation, conservative treatment, or fertility preservation, or inability to tolerate standard surgery due to comorbidities.\n8. Adequate organ function within 14 days prior to enrollment.\n9. Good follow-up conditions and signed informed consent.\n\nExclusion Criteria:\n\n1. Presence of active autoimmune disease, or long-term requirement for immunosuppressive agents;\n2. Prior treatment with immune checkpoint inhibitors;\n3. Concurrent persistent or active infections, such as hepatitis B, hepatitis C, etc.;\n4. Concurrent severe dysfunction of vital organs including heart, lung, liver and kidney: alanine aminotransferase\u002Faspartate aminotransferase elevated more than 3 times the upper limit of normal (ULN) and unresponsive to liver-protective therapy; serum creatinine ≥1.5 × ULN; abnormal thyroid function; history of heart failure, unstable angina pectoris, severe arrhythmia, myocarditis, interstitial lung disease, non-infectious pneumonitis or active pulmonary infection, etc.;\n5. Other active malignant tumors (except cured basal cell carcinoma of the skin, cervical carcinoma in situ, etc.);\n6. Known hypersensitivity to any component of the study drug;\n7. Pregnant or breastfeeding women;\n8. Any severe or unstable concomitant disease that, in the investigator's judgment, renders the subject ineligible for this study.","FEMALE","18 Years","75 Years",{"count":19,"type":20},48,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","To investigate the efficacy and safety of immune checkpoint inhibitors as a non-surgical (surgery-avoiding) treatment in patients with stage I-II MSI-H\u002FdMMR endometrial cancer.",[26],"MMRd Endometrial Cancer of Stage I~II",[28,29,30],"endometrial cancer","stage I~II","MMRd","NOT_YET_RECRUITING","2026-07-25",{"date":34,"type":35},"2026-07-28","ACTUAL",{"date":37,"type":20},"2026-07-20",{"date":39,"type":20},"2030-07-20",{"name":41,"class":42},"Wang Jianliu","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100621985","phase-2-intrauterine-injection-of-type-iii-collage-in-fst-of-ecaeh-100621985","NCT07377734","Intrauterine Injection of Type III Collage in FST of EC\u002FAEH","A Multicenter, Randomized, Open-Label, Controlled Clinical Trial of Intrauterine Injection of Recombinant Humanized Type III Collage in the Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia","2026ColECFerSp","Inclusion Criteria:\n\n1. Pathological diagnosis of endometrioid adenocarcinoma (G1 or G2) or atypical endometrial hyperplasia.\n2. For patients with endometrial cancer, magnetic resonance imaging (MRI) or ultrasound must confirm that the lesion is confined to the endometrium or invades less than 1\u002F2 of the myometrium (i.e., FIGO 2009 Stage IA).\n3. Age ≤ 45 years.\n4. Desire to preserve fertility and signed informed consent.\n5. No serious medical comorbidities (e.g., severe liver or renal dysfunction).\n6. No contraindications to progestin therapy or pregnancy.\n7. No evidence of distant metastasis on imaging.\n\nExclusion Criteria:\n\n1. Tumor invasion \\> 1\u002F2 of the myometrium, or FIGO (2009) Stage IB and above.\n2. Tumor differentiation grade G3 or non-endometrioid adenocarcinoma.\n3. Coexistence of other malignant tumors.\n4. Contraindications to conservative treatment or use of the study drugs.\n5. Known allergy to recombinant protein components.\n6. Acute genital tract inflammation or untreated abnormal vaginal discharge within 2 weeks prior to enrollment.\n7. Previous treatment with high-potency progestin for more than 1 month.","45 Years",{"count":53,"type":20},30,[23],"The goal of this clinical trial is to learn if intrauterine injection of \"Recombinant Humanized Type III Collagen Lyophilized Fibers\" works to treat endometrial cancer or atypical hyperplasia in patients seeking fertility-preserving treatment. It will also learn about the safety of this intervention.The main questions it aims to answer are:\n\n1. Does the combination of recombinant humanized type III collagen and progestin significantly increase the tumor remission rate at 6 months compared to progestin alone?\n2. What medical problems do participants have when receiving this treatment (e.g., allergic reactions, abnormal inflammatory markers, or histocompatibility issues)? Researchers will compare \"recombinant humanized type III collagen plus progestin (experimental group)\" to \"high-dose progestin alone (control group)\" to see if the combination therapy is more effective for fertility preservation.\n\nParticipants will:\n\n1. Take high-dose progestin (such as Medroxyprogesterone Acetate or Megestrol Acetate) orally every day.\n2. If assigned to the experimental group, receive one intrauterine submucosal injection of collagen via hysteroscopy at months 0, 1, and 2, for a total of 3 injections.\n3. Visit the clinic once every 3 months for treatment evaluation and follow-up, which includes hysteroscopic endometrial biopsy, imaging (such as transvaginal ultrasound), and safety tests for relevant biochemical indicators.",[57,58],"Atypical Endometrial Hyperplasia","Endometrial Cancer","RECRUITING","2026-03-24",{"date":62,"type":35},"2026-03-30",{"date":64,"type":35},"2026-01-30",{"date":66,"type":20},"2029-12-30",{"name":41,"class":42},1,""]